Biostage, Inc.
Form 8-K
June 07, 2018

UNITED STATES	
SECURITIES AND EXC	HANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2018

BIOSTAGE, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35853 45-5210462

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

84 October Hill Road, Suite 11, Holliston, MA 01746

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (774) 233-7300

Edgar Filing: Biostage, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
5.02. Compensatory Arrangements of Certain Officers.

On June 3, 2018 and June 4, 2018, John J. Canepa and Blaine H. McKee respectively resigned as members of the Board of Directors and Audit Committee Biostage, Inc., or the Company. Mr. Canepa's and Mr. McKee's resignations were not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices. The Company is actively in the process of identifying highly qualified candidates to replace Mr. Canepa and Mr. McKee on the Board and its Audit Committee.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSTAGE,

INC.

(Registrant)

June 7, 2018 /s/ Thomas

McNaughton

Thomas

(Date) McNaughton

Chief Financial

Officer